A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer
Year: 2024
Type: article
Abstract: What is this summary about? This is a summary of the results of a study called PHAROS. This study looked at combination treatment with encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®). This combination of medicines was studied in people with metastatic non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Metastatic means that the cancer has spread to other parts of the body. All people in this study had a type of NSCLC that has a change in a gene called BRAF termed a BRAF V600E mutation. A gene is a part of the DNA that has instructions for making things that your body needs to work, and the BRAF V600E mutation contributes to the growth of the lung cancer.What were the results? In this study, 98 people with BRAF V600E-mutant metastatic NSCLC were treated with the combination of encorafenib and binimetinib (called encorafenib plus binimetinib in this summary). Before starting the study, 59 people had not received any treatment for their metastatic NSCLC, and 39 people had received previous anticancer treatment. At the time of this analysis, 44 (75%) out of 59 people who did not receive any treatment before taking encorafenib plus binimetinib had their tumors shrink or disappear. Eighteen (46%) out of 39 people who had received treatment before starting encorafenib plus binimetinib also had their tumors shrink or disappear. The most common side effects of encorafenib plus binimetinib were nausea, diarrhea, fatigue, and vomiting.What do the results mean? These results support the use of encorafenib plus binimetinib combination treatment as a new treatment option in people with BRAF V600E-mutant metastatic NSCLC. The side effects of encorafenib plus binimetinib in this study were similar to the side effects seen with encorafenib plus binimetinib in people with a type of skin cancer called metastatic melanoma.
Source: Future Oncology
Authors: Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussein, Gregory A Otterson, Ibiayi Dagogo-Jack, Jonathan W Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E Johnson
Institutions: Memorial Sloan Kettering Cancer Center, Leiden University Medical Center, Samsung Medical Center, Sungkyunkwan University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Winship Cancer Institute, The University of Texas MD Anderson Cancer Center, Tennessee Oncology, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Florida Cancer Specialists & Research Institute, Institut Català d'Oncologia, Hospital Universitario Puerta de Hierro Majadahonda, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Massachusetts General Hospital, University of California, Los Angeles, Washington University in St. Louis, Pfizer (United States), Pfizer (Italy), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4391840902